NEW YORK, NY / ACCESSWIRE / February 6, 2017 / The Biotech Industry has experienced some steep losses in recent years, but has begun to show some signs of stabilization in 2017. The Industry was home to some impressive gains for investors from early 2013 to about the halfway mark of 2015. Over that period, the major biotech ETFs skyrocketed more than 150 percent. In comparison the S&P 500 Index posted a gain of approximately 50 percent during the same period. The iShares Nasdaq Biotechnology Index ETF and the SPDR S&P Biotech ETF have risen 6.7 percent and 11.5 percent, respectively year-to-date. The iShares Nasdaq Biotechnology Index ETF and the SPDR S&P Biotech ETF both fell approximately 40 percent from their peak in mid-July 2015 through February 2016.
Register today for a free membership and gain access to daily research reports at: RDInvesting.com
One of the biggest catalysts for impressive gains in the biotech industry has been acquisition talks. There were 326 biotech mergers & acquisitions deals completed in 2016, which were worth a total of approximately $91 billion. Experts have forecasted that number to rise in 2017 as a recent Deloitte study showed research & development productivity of 12 of the biggest biopharma companies fell to a 7-year low in 2016. Additionally, the study showed that the top 14 biopharma firms with the most cash held a total of $220 billion in cash and marketable securities at the end of the third quarter 2016.
Let's Take a Closer Look at Today's Trending Biotech Tickers
MYOS RENS Technology's shares spiked 37.22 percent to close at $3.65 a share Friday. The stock traded between $2.61 and $6.00 on volume of 25.54 million shares traded. MYOS is the owner of Fortetropin, the world's first clinically demonstrated myostatin reducer. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery.
"It has become clear that myostatin is a key clinical target to address fundamental issues such as sarcopenia, inflammation and aging. MYOS RENS continues to lead in the development of products that target myostatin, and we believe, is the only company that has a safe and effective product on the market to modulate myostatin," said Dr. Robert Hariri, U.S. Chairman of MYOS RENS Technology, in a press release on January 30th.
On February 3rd, the company announced an institutional investor has agreed to purchase approximately $2.125 million of the Company's common stock in a registered direct offering under which the Company agreed to sell 500,000 shares of its common stock at a per share price of $4.25. The closing of the registered direct offering is expected to take place on or about February 8, 2017, subject to conditions.
Actinium Pharmaceuticals shares surged 32.04 percent to close at $1.36 a share Friday. The stock traded between $1.07 and $1.38 on volume 5.52 million shares traded. Actinium is developing innovative targeted therapies for patients with cancers lacking effective treatment options. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.
On January 18th, the company announced that it has appointed Dr. Mark Berger as Chief Medical Officer. "Dr. Berger joins Actinium with significant drug development expertise that includes the planning and execution of clinical trials that led to the FDA approval of Mylotarg for acute myeloid leukemia (AML) while at Wyeth Research (now Pfizer), and Tykerb for breast cancer while at GlaxoSmithKline," the company said in the press release.
Today's Features Includes:
MYOS RENS Technology Inc. (NASDAQ: MYOS)
Actinium Pharmaceuticals Inc. (NYSE MKT: ATNM)
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.